{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-037840","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2026-08-13T20:45:32+00:00","discovered_at":"2026-08-13T20:46:01.036413+00:00","generated_at":"2026-08-13T20:46:07.140074+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Calidi Biotherapeutics Q2 2026 net loss narrows to $4.2M; FDA agrees on CLD-401 path","bullets":["Net loss attributable to common stockholders: $4.2M ($2.94/share) vs $5.7M ($31.75/share) in Q2 2025, adjusted for 1-for-16 reverse split.","G&A expenses cut 48% to $1.6M from $3.1M; R&D flat at $2.6M.","Cash and restricted cash $4.3M at June 30, 2026 vs $5.8M at Dec 31, 2025.","FDA pre-IND feedback for CLD-401 supports first-in-human study; first patient dosing targeted Q1 2027.","Added Corsee Sanders, Ph.D. (ex-Genentech/Roche, Celgene) to Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-037840","json":"https://secwatch.observer/filing/0001493152-26-037840.json","markdown":"https://secwatch.observer/filing/0001493152-26-037840.md","text":"https://secwatch.observer/filing/0001493152-26-037840.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226037840/0001493152-26-037840-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226037840/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:46:07.140074+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}